Due to the impact of the Russia-Ukraine conflict and the COVID-19 pandemic, the global economy is expected to recover, leading to an expansion of the World Thrombosis Drugs Market size from USD million in 2021 to USD million in 2022, with a projected CAGR that will generate substantial revenue until 2030. As a result, consumers gain valuable knowledge about the industry and its organizations from past, present, and future perspectives, enabling informed investment decisions and resource allocation. This research report provides up-to-date analysis and forecasts for various market segments and geographical regions. It offers insights and analysis based on in-depth consultations with key stakeholders, including CEOs, Managers.
Thrombosis is a medical condition characterized by the formation of blood clots within blood vessels, which can obstruct the normal flow of blood. Thrombosis drugs are designed to treat or prevent the formation of these blood clots, which can lead to various thrombotic events. These drugs, including anticoagulants and thrombin inhibitors, reduce the blood’s clotting ability and, consequently, the risk of thrombotic events. Thrombosis drug applications encompass conditions such as deep vein thrombosis (DVT), pulmonary embolism, and atrial fibrillation.
Request To Download Free Sample of This Strategic Report:- https://www.reportocean.com/industry-verticals/sample-request?report_id=IR267
Shockingly, according to Thrombosis UK estimates, an individual dies from venous thromboembolism (VTE) every 6 seconds globally, with 1 in 4 deaths linked to blood clots. Additionally, the Centers for Disease Control and Prevention (CDC) reports that approximately 900,000 people are affected by DVT or pulmonary embolism, with 1 to 2 individuals per 1,000 affected in the United States each year.
The thrombosis drugs market is driven by an increasing burden of cardiovascular diseases and trauma cases, as well as a growing elderly and obese population. The introduction of novel drugs into the market and ongoing research efforts aimed at developing innovative drugs offer opportunities for improved and more effective treatments, expected to support market growth over the next five years. However, side effects associated with thrombosis drugs and a lack of public awareness about thromboembolic conditions may hinder market growth.
Market Analysis
The global thrombosis drugs market is estimated to witness a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period from 2018 to 2024. The market is analyzed based on three key segments: drug class, indication, and regions.
Drug Class Analysis
The thrombosis drugs market is divided into three drug classes: factor Xa inhibitors, low molecular weight heparin, and P2Y12 platelet inhibitors. The factor Xa inhibitor segment held a significant market share in 2017 and is expected to exhibit a high CAGR during the forecast period. The strong preference for anticoagulant drugs is anticipated to drive growth in this segment.
Indication Analysis
Indications for thrombosis drugs include pulmonary embolism, atrial fibrillation, and deep vein thrombosis. The pulmonary embolism segment accounted for a significant share in 2017 and is projected to grow at a high CAGR during the forecast period. Increasing efforts to develop cost-effective drugs and the large patient pool with pulmonary embolism are likely to drive market growth in the next five years.
Request To Download Free Sample of This Strategic Report:- https://www.reportocean.com/industry-verticals/sample-request?report_id=IR267
Region Analysis
The regions covered in the report include North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America is the dominant shareholder in the global thrombosis drugs market, followed by Europe. Factors contributing to North America’s dominance include the availability of novel anticoagulants, the presence of major market players, increased disease awareness, and rising healthcare expenditure. Asia Pacific is the fastest-growing region, driven by an increase in the prevalence of cardiovascular diseases and other age-related chronic conditions, growing healthcare expenditure, and improved access to healthcare services.
Key Players
Key players in the market include Johnson & Johnson, Aspen Pharmacare Holdings, Sanofi S.A., Bayer AG, Boehringer Ingelheim, and Bristol-Myers Squibb. Additional prominent players in the market include AstraZeneca plc, Daiichi Sankyo, Pfizer, Inc., and Baxter International Inc.
Competitive Analysis
The thrombosis drugs market has experienced increasing demand in recent years, leading many companies to collaborate on the development of novel drugs. New thrombosis drugs have received global approval and launch. For example, in December 2017, Aurobindo Pharma received FDA approval to manufacture and market its generic version of Fondaparinux Sodium injection, used for preventing DVT. Janssen Pharmaceuticals announced the launch of XARELTO (rivaroxaban) in late 2017 for reducing the sustained risk of recurrent venous thromboembolism (VTE). In June 2017, Portola launched its drug betrixaban (Bevyxxa) in the US market. In June 2018, Biogen entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007, a plasminogen inhibitor, and backup compounds.
Benefits
The report offers comprehensive details about the products provided by thrombosis drug companies in various therapeutic areas and regions. This information allows key stakeholders to understand major trends, drivers, investments, and initiatives by vertical players. Moreover, the report outlines the significant challenges that may impact market growth and provides key business opportunities for stakeholders to expand their businesses and capture revenue in specific verticals. This information is invaluable for making informed investment decisions and developing business expansion strategies.
Key Stakeholders
- Researchers
- Healthcare Professionals
- Pharmaceutical Companies
- Regulatory Authorities
Region/Country Covered in the Report
- North America
- Europe
- Asia Pacific
- Rest of the World (ROW)
Request To Download Free Sample of This Strategic Report:- https://www.reportocean.com/industry-verticals/sample-request?report_id=IR267
Key Players Covered in the Report
- Johnson & Johnson
- Aspen Pharmacare Holdings
- Sanofi S.A.
- Bayer AG
- Boehringer Ingelheim
- Bristol-Myers Squibb
- AstraZeneca plc
- Daiichi Sankyo
- Pfizer, Inc.
- Baxter International Inc.
Market Dynamics:
Surging air traffic:
- As the global aviation industry continues to expand, there is a corresponding increase in market demand.
Heightened emphasis on safety and reliability:
- The aerospace and defense sector places significant importance on ensuring safety and reliability, which drives the need for top-notch market offerings.
Growing commitment to environmental sustainability:
- The aerospace and defense industry is increasingly dedicated to reducing its carbon footprint, resulting in the adoption of sustainable aviation fuels.
Escalating globalization:
- The growth of international trade and travel propels the demand for market solutions.
Increasing desire for private air transportation:
- The rising number of affluent individuals and their preference for exclusive air travel are generating fresh opportunities in the market.
Expanding utilization of digital fuel management systems:
- The integration of digital fuel management systems facilitates efficient fuel consumption and reduces associated costs.
Advancements in fuel cell technology:
- Ongoing developments in fuel cell technology unlock new possibilities for the production of sustainable market alternatives.
Mounting demand for air cargo transportation:
- The flourishing e-commerce sector fuels an increasing need for air cargo transportation, thereby driving the demand for market offerings.
Rising defense budgets:
- Governments worldwide are augmenting their defense spending, leading to heightened market demand.
Request full Report:– https://www.reportocean.com/industry-verticals/sample-request?report_id=IR267
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean is the world’s leading research company, known for its informative research reports. We are committed to providing our clients with both quantitative and qualitative research results. As a part of our global network and comprehensive industry coverage, we offer in-depth knowledge, allowing informed and strategic business conclusions to report. We utilize the most recent technology and analysis tools along with our own unique research models and years of expertise, which assist us to create necessary details and facts that exceed expectations.
Get in Touch with Us:
Report Ocean:
Email:sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
Tel:+1888 212 3539 (US – TOLL FREE)
Website:https://reportocean.com
/Advanced%20Micro%20Devices%20Inc_%20office%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)
/CPU%20Chip.jpg)
